• LAST PRICE
    3.3500
  • TODAY'S CHANGE (%)
    Trending Down-0.1000 (-2.8986%)
  • Bid / Lots
    3.2800/ 2
  • Ask / Lots
    3.6900/ 1
  • Open / Previous Close
    3.4500 / 3.4500
  • Day Range
    Low 3.3201
    High 3.4500
  • 52 Week Range
    Low 2.7100
    High 8.4900
  • Volume
    42,833
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.45
TimeVolumeRPTX
09:32 ET2933.45
09:50 ET2003.41
10:06 ET1003.385
10:14 ET2003.4
10:19 ET4003.4
10:35 ET4933.38
10:46 ET1663.35
10:48 ET1003.375
10:53 ET1003.375
11:04 ET1003.35
11:06 ET1003.345
11:08 ET9993.3201
11:09 ET41153.36
11:15 ET1003.365
11:22 ET6503.36
11:42 ET1003.36
11:49 ET1003.36
11:54 ET2003.38
11:56 ET1003.39
12:12 ET24433.3899
12:21 ET1003.375
12:23 ET9233.4
12:30 ET11253.363
12:36 ET3003.36
01:01 ET3003.37
01:15 ET48543.35
01:39 ET5003.37
02:02 ET2603.37
02:20 ET1003.38
02:27 ET1003.38
02:42 ET20003.355
03:20 ET1993.3416
03:30 ET3003.345
03:45 ET6143.34
03:50 ET9503.335
03:52 ET2003.35
03:56 ET1003.3484
03:57 ET23073.33
03:59 ET88153.35
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRPTX
Repare Therapeutics Inc
146.4M
-2.1x
---
United StatesIPHA
Innate Pharma SA
151.0M
-4.1x
---
United StatesADAP
Adaptimmune Therapeutics PLC
178.2M
-2.1x
---
United StatesCSBR
Champions Oncology Inc
51.5M
-15.4x
---
United StatesDTIL
Precision BioSciences Inc
58.4M
-62.8x
---
United StatesMGX
Metagenomi Inc
78.7M
-0.8x
---
As of 2024-10-31

Company Information

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Contact Information

Headquarters
7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Thomas Civik
President, Chief Executive Officer, Director
Lloyd Segal
Chief Financial Officer, Executive Vice President
Steve Forte
Executive Vice President, Chief Scientific Officer
Michael Zinda
Executive Vice President, Chief Medical Officer
Maria Koehler

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$146.4M
Revenue (TTM)
$68.7M
Shares Outstanding
42.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.71
EPS
$-1.63
Book Value
$5.03
P/E Ratio
-2.1x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
---
Operating Margin
-139.46%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.